Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome

NCT00081458 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Short Bowel Syndrome

Interventions

DRUG: Placebo
DRUG: Teduglutide 0.05 mg/kg/d
DRUG: Teduglutide 0.1 mg/kg/d

Sponsor

Shire